Obalon Therapeutics (NASDAQ:OBLN) gains 55.5% after announcing the FDA approval for its Navigation System, which removes the need for an x-ray when placing the Obalon Balloon System obesity treatment. The Navigation System instead uses magnetic resonance.
Commercial availability of the Navigation System is expected in Q1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.